Dow/Chromatin combine GMO technologies
Dow AgroSciences has reached an exclusive research and licensing agreement with the US biotechnology company, Chromatin (Chicago, Illinois), to combine Dow’s Exzact gene targeting with Chromatin’s mini-chromosome technology in the development of genetically modified maize, soybeans and canola. The deal creates a “technology synergy that delivers flexibility and efficiencies for modifying trait combinations on the mini-chromosome”, the companies point out. A second agreement grants Dow non-exclusive rights to the mini-chromosome technology. Chromatin has similar deals with Monsanto, Syngenta and Bayer CropScience ( Agrow No 575, p 3). Dow licensed the Exzact technology from Sangamo Biosciences last year ( Agrow No 546, p 3).